Mirum Pharmaceuticals Inc. (MIRM) carries a Roarable Rating of C (Hold) with 64/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Mirum Pharmaceuticals Inc. (MIRM) advanced +0.68% to $86.39 as options desks priced 54% call premium vs. 46% put protection around the $85 max-pain magnet. Solid 41% profit margin (-4% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.
Is ANAB a good stock to buy? We came across a bullish thesis on AnaptysBio, Inc. on TripleS Special Situations’s Substack. Since the thesis was published on June 15th, ANAB shares have pulled back as uncertainty over its
Recursion Pharmaceuticals (RXRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mirum Pharmaceuticals has delivered a very strong multi year share price run, and with the stock recently closing at US$85.56 the live question is whether that level can be explained by what the business is generating in
Mirum Pharmaceuticals (MIRM) is back on investors’ radar after new data from its PROGRESS trial showed that ATEBRIOZ reduced heterotopic ossification lesion volume and improved joint mobility in younger pediatric FOP pat
FOSTER CITY, Calif., October 27, 2026--Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026
Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FOSTER CITY, Calif., October 26, 2026--Mirum Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Patients Aged 6 to <12 Years with FOP
- Zilurgisertib reduced total HO lesion volume and improved clinician-assessed joint mobility; no zilurgisertib-treated patients developed new HO lesions- Mirum plans to submit an sNDA in H1 2027 to expand the ATEBRIOZ
FOSTER CITY, Calif., October 21, 2026--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
TD Cowen analyst Joseph Thome maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $140 to $145.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +54.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on MIRM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for MIRM. Explore sector supply chains on /butterfly.
Why MIRM Stock advanced +0.68% Today — RQD Quant Desk Flash. Solid 41% profit margin (-4% return on capital), mixed timing at current multiples—hold if owned, no rush to chase.